NGS Services Market

The NGS services market is projected to reach USD 9.37 billion in 2031 from USD 3.96 billion in 2026, at a CAGR of 18.8% during the forecast period.

Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), Eurofins Scientific (Luxembourg), Azenta US Inc. (US), BGI Group (China), Revvity (US), Agilent Technologies, Inc. (US), PacBio (US), Oxford Nanopore Technologies plc (UK), F. Hoffmann-La Roche Ltd. (Switzerland), LGC Limited (UK), WuXi Biologics (China), QIAGEN (Germany), Labcorp (US), IQVIA (US), and Twist Bioscience (US) are the key players in this market.

To know about the assumptions considered for the study download the pdf brochure

These market players have adopted various approaches, including service launches, collaborations, acquisitions, agreements, and expansions, to enhance their market positions. In March 2026, Illumina and Labcorp expanded their collaboration to broaden access to precision oncology testing using NGS, including distributed cancer biomarker testing, evidence generation, and development of testing solutions for unmet clinical needs.

In May 2025, Eurofins BioPharma Product Testing added GMP sequence identity testing using NGS at its Lancaster laboratory. The validated service supports sequence confirmation and variant detection for plasmids, AAV, and lentiviral/retroviral vectors, with associated bioinformatics analysis.

Illumina, Inc. (US): Illumina is a major participant in the NGS services market, supporting customers with sequencing, genomic analysis, and customized workflow services across research and clinical applications. Its service capabilities support whole-genome sequencing, targeted sequencing, RNA sequencing, population genomics, and other high-throughput genomic studies. Illumina works with pharmaceutical and biotechnology companies, healthcare organizations, and research institutes on projects involving biomarker discovery, precision medicine, oncology, rare diseases, and translational research. Its strong sequencing expertise, scalable infrastructure, and bioinformatics capabilities support complex projects that require high data quality, large sample volumes, and integrated genomic analysis.

Thermo Fisher Scientific Inc. (US): Thermo Fisher Scientific provides NGS-related services spanning sample processing, sequencing, assay development support, and genomic data analysis. Its capabilities support targeted sequencing, whole-genome and exome sequencing, RNA sequencing, and customized NGS studies for pharmaceutical, biotechnology, clinical, and academic customers. The company also supports genomic research programs involving oncology, infectious diseases, biomarker development, and drug discovery. Thermo Fisher benefits from broad life sciences capabilities and established laboratory infrastructure, enabling customers to outsource selected or complete NGS workflows. Its ability to combine sequencing expertise with bioinformatics and application-specific support strengthens its position in the NGS services market.

Eurofins Scientific (Luxembourg): Eurofins Scientific offers a broad portfolio of NGS services through its genomics and laboratory services businesses. Its capabilities include whole-genome sequencing, whole-exome sequencing, targeted sequencing, RNA sequencing, metagenomics, amplicon sequencing, and bioinformatics analysis. The company serves pharmaceutical and biotechnology companies, academic institutions, healthcare organizations, and other research customers across drug discovery, microbiology, oncology, infectious disease research, and genomics studies. Eurofins also provides sample preparation, library preparation, sequencing, quality control, and downstream data analysis as part of integrated project workflows. Its extensive laboratory network, broad service portfolio, and ability to manage both routine and customized sequencing projects support its strong position in the NGS services market.

Market Ranking

The NGS services market is competitive, with leading sequencing and life sciences companies expanding their service capabilities across research, clinical, and drug development applications. Key players include Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), and Eurofins Scientific (Luxembourg). Illumina strengthens its position through high-throughput sequencing services, population genomics capabilities, and genomic data analysis support for applications such as oncology, rare diseases, precision medicine, and translational research. Thermo Fisher Scientific provides NGS services covering sample processing, sequencing, customized assay support, and bioinformatics analysis across targeted sequencing, whole-genome sequencing, exome sequencing, and RNA sequencing workflows. Eurofins Scientific offers a broad sequencing services portfolio including whole-genome sequencing, whole-exome sequencing, targeted sequencing, RNA sequencing, metagenomics, and downstream bioinformatics. Collectively, these companies support end-to-end and customized NGS workflows for pharmaceutical and biotechnology companies, hospitals and clinical laboratories, and academic research institutes. Their extensive laboratory infrastructure, sequencing expertise, scalable capacity, and data-analysis capabilities strengthen their competitive position in the global NGS services market.

Related Reports:

NGS Services Market by Type (Presequencing [Sample Prep, Quality Control], Sequencing [RNA, ChIP, Whole Genome], Bioinformatics), Workflow, Application (Diagnostics, Cancer, Drug Discovery, Pharmacogenomic), End User, Region - Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]